Title:
SIROLIMUS-CONTAINING TOPICAL DRUG FOR TREATING SKIN HARDENING IN SYSTEMIC SCLERODERMA
Document Type and Number:
WIPO Patent Application WO/2024/034627
Kind Code:
A1
Abstract:
A novel drug for treating or preventing skin hardening in systemic scleroderma has been discovered due to the discovery that skin hardening in systemic scleroderma can be ameliorated by the administration of a sirolimus-containing topical drug to the skin.
Inventors:
MOTEGI SEI-ICHIRO (JP)
Application Number:
PCT/JP2023/029015
Publication Date:
February 15, 2024
Filing Date:
August 09, 2023
Export Citation:
Assignee:
UNIV GUNMA NAT UNIV CORP (JP)
International Classes:
A61K31/436; A61K9/06; A61K9/08; A61K9/10; A61K9/70; A61P17/00; A61P29/00; C12N15/12; C12N15/28
Foreign References:
| JP2022521006A | 2022-04-04 |
Other References:
GOC, A . ET AL.: "TGF(3-and bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR", J CELL PHYSIOL., vol. 226, no. 11, 2011, pages 3004 - 3013, XP055563291, DOI: 10.1002/jcp.22648
TAMAKI, Z. ET AL.: "Effects of the immunosuppressant rapamycin on the expression of human a2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts", J. DERMATOL. SCI., vol. 74, no. 3, 2014, pages 251 - 259, XP028644924, DOI: 10.1016/j.jdermsci.2014.02.002
TAMAKI, Z. ET AL.: "Effects of the immunosuppressant rapamycin on the expression of human a2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts", J. DERMATOL. SCI., vol. 74, no. 3, 2014, pages 251 - 259, XP028644924, DOI: 10.1016/j.jdermsci.2014.02.002
Attorney, Agent or Firm:
IP FIRM SHUWA (JP)
Download PDF: